| Literature DB >> 32128090 |
Zahra Mir1, Narges Nodeh Farahani1, Sara Abbasian1, Faranak Alinejad2, Mahboubeh Sattarzadeh2, Ramin Pouriran3, Mostafa Dahmardehei2, Mehdi Mirzaii4, Seyed Sajjad Khoramrooz5, Davood Darban-Sarokhalil1.
Abstract
OBJECTIVES: The present study investigated the prevalence of genes encoding for exotoxins, adhesion and biofilm factors in Staphylococcus aureus isolates obtained from samples in a referral burn hospital in Tehran, Iran.Entities:
Keywords: Adhesin and biofilm genes; Burn; Iran; MRSA; Virulence factors
Year: 2019 PMID: 32128090 PMCID: PMC7038426 DOI: 10.22038/ijbms.2019.34908.8291
Source DB: PubMed Journal: Iran J Basic Med Sci ISSN: 2008-3866 Impact factor: 2.699
Primers and product size of PCR for detection of the exotoxins and biofilm genes
| Genes | Sequence (5-3) | Product size (bp) | Reference |
|---|---|---|---|
|
| F-GTCAAGCAGTTATTAACACCAGAC | 423 |
|
Cycles and condition of multiplex PCRs in this study
| Genes | Cycles of amplification | Initial denaturation | Denaturation | Annealing | Extension | Final extension | Reference |
|---|---|---|---|---|---|---|---|
|
| 30 | 5min at 94 | 45s at 94 | 45s at 57 | 1min at 72 | 5min at 72 |
|
|
| 25 | 5min at 94 | 1 min at 94 | 1min at 55 | 1min at 72 | 10 min at 72 | |
|
| 30 | 5min at 94 | 45s at 92 | 45s at 49 | 1min at 72 | 7min at 72 | |
|
| 30 | 5min at 94 | 45s at 94 | 45s at 57 | 1min at 72 | 5min at 72 | |
|
| 35 | 5min at 94 | 2min at 94 | 2min at 57 | 1min at 72 | 7min at 72 | |
|
| 30 | 5min at 95 | 40s at 95 | 40s at 54 | 45s at 72 | 5min at 72 |
Antibiotics resistance in MRSA and MSSA strains in patients, surfaces and personnel in burn Shahid Motahari Hospital, Tehran, Iran
| Antibiotics | Patients N (%) | Surfaces N (%) | Personnel N (%) | |||
|---|---|---|---|---|---|---|
| MRSA(79) | MSSA(44) | MRSA(22) | MRSA(7) | MSSA(8) | MSSA(7) | |
| Penicillin | 79 (100) | 16 (36) | 22 (100) | 4 (50) | 7 (100) | 3(43) |
| Gentamicin | 67 (85) | 2 (5) | 21 (95) | 2 (25) | 5 (71) | 0 |
| Clindamycin | 62 (78) | 7 (16) | 18 (82) | 2 (25) | 1 (14) | 0 |
| Erythromycin | 68 (86) | 9 (20) | 18 (82) | 2 (25) | 2 (29) | 0 |
| Nitrofurantoin | 1 (1) | 0 | 0 | 1(13) | 0 | 0 |
| Rifampicin | 48 (61) | 3 (7) | 17 (77) | 0 | 5 (71) | 0 |
| Quinupristin- | 0 | 0 | 0 | 0 | 0 | 0 |
| Linezolid | 0 | 0 | 0 | 0 | 0 | 0 |
| Tigecycline | 0 | 0 | 0 | 0 | 0 | 0 |
| Cefoxitin | 79 (100) | 0 | 22 (100) | 0 | 7 (100) | 0 |
| Tetracycline | 61 (77) | 11(25) | 18 (82) | 2 (25) | 4 (57) | 0 |
| Norfloxacin | 68 (86) | 6 (14) | 20 ( 91) | 2 (25) | 6 (86) | 0 |
| Mupirocin | 62 (78) | 6 (14) | 18 (82) | 2 (25) | 7 (100) | 1(14) |
| Trimethoprim- | 32 (41) | 6 (14) | 8 (36) | 0 | 1 (14) | 0 |
| Imipenem | 79 (100) | 4 (9) | 22 (100) | 3 (38) | 7 (100) | 0 |
| Chloramphenicol | 3 (4) | 1 (2) | 0 | 0 | 0 | 0 |
MRSA: methicillin resistant Staphylococcus aureus; MSSA: methicillin-susceptible Staphylococcus aureus
Figure 1The results of statistical analysis on virulence genes among MRSA and MSSA isolates
Distribution of virulence genes in Staphylococcus aureus, MRSA and MSSA isolates of patients, surfaces and personnel in burn Shahid Motahari Hospital, Tehran, Iran
| Virulence genes | Patients (123) | Surfaces (30) | Personnel(14) | |||
|---|---|---|---|---|---|---|
| MRSA (79) N (%) | MSSA (7) | MSSA (44) | MRSA (22) | MSSA (8) | MRSA (7) | |
|
| ||||||
|
| 65 (82.2) | 35 (79.5) | 22 (100) | 7 (87.5) | 7 (100) | 7 (100) |
|
| 45 (56.9) | 26 (59) | 18 (81.8) | 4 (50) | 3 (42.8) | 3 (42.8) |
|
| 49 (62) | 34 (77.2) | 19 (86.3) | 7 (87.5) | 5 (71.4) | 3 (42.8) |
|
| 59 (74.6) | 25 (56.8) | 20 (90.9) | 5 (62.5) | 7 (100) | 4 (57.1) |
|
| ||||||
|
| 17 (21.5) | 7 (15.9) | 2 (9) | 3 (37.5) | 1 (14.2) | 0 |
|
| 74 (93.6) | 40 (90.9) | 21 (95.4) | 7 (87.5) | 7 (100) | 6 (85.7) |
|
| 34 (43) | 5 (11.3) | 14 (63.6) | 1 (12.5) | 4 (57.1) | 0 |
|
| 70 (88.6) | 38 (86.3) | 22 (100) | 6 (75) | 7 (100) | 7 (100) |
| 5 (6.3) | 13 (29.5) | 0 | 1 (12.5) | 0 | 1 (14.2) | |
|
| 5 (6.3) | 11 (25) | 2 (9) | 0 | 0 | 0 |
|
| ||||||
|
| 0 | 1 (2.2) | 0 | 0 | 0 | 0 |
|
| 56 (70.8) | 28 (63.6) | 21 (95.4) | 6 (75) | 6(85.7) | 4 (57.1) |
|
| 64 (81) | 37 (84) | 21 (95.4) | 8 (100) | 7(100) | 6 (85.7) |
MRSA: methicillin resistant Staphylococcus aureus; MSSA: methicillin-susceptible Staphylococcus aureus
Antibiotic resistance profile and gene combination patterns in MRSA isolates of burn hospital
| Resistance profile | Gene combination | ||
|---|---|---|---|
|
|
|
| |
| GM, MUP, RP, NOR, E, CD | 36 (33%) | 33 (30.5%) | 25 (23.1%) |
| PG, IMI, T, E, CD | 46 (42.5%) | 42 (38.5%) | 40 (37%) |
| GM, MUP, NOR, RP | 44 (40.7%) | 43 (39.8%) | 35 (32.4%) |
| MG, MUP, RP, NOR, E, CD, T, PG, IMI | 33 (30.5%) | 31 (28.5%) | 25 (23.5%) |
PG, Penicillin; MG, Gentamicin; CD, Clindamycin; E, Erythromycin; RP, Rifampicin; T, Tetracycline; NOR, Norfloxacin; MUP, Mupirocin; IMI, Imipenem;
Figure 2The results of statistical analysis on antibiotic susceptibility tests among MRSA and MSSA isolates